# EDGAR Filing Document

**Accession Number:** 0001507673
**File Stem:** 0001507673-25-000031
**Filing Date:** 2025-8
**Character Count:** 11501
**Document Hash:** 1dde013ee983c7eb5196ffd1dbe3553b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001507673-25-000031.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001507673-25-000031

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RP Management, LLC
- **CENTRAL INDEX KEY:** 0001507673

**ORGANIZATION NAME:**
- **EIN:** 611450238
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-19261
- **FILM NUMBER:** 251281224

**BUSINESS ADDRESS:**
- **STREET 1:** 110 EAST 59TH STREET
- **STREET 2:** SUITE 3300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-883-0200

**MAIL ADDRESS:**
- **STREET 1:** 110 EAST 59TH STREET
- **STREET 2:** SUITE 3300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001507673

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** RP Management, LLC

**Address:** 110 East 59th Street, New York, NY 10022

**Telephone number:** 212-883-0200

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-19261

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 1

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                 | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                                                                                                                                                                                                                                            | VOTE CATEGORY      |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| CYTOKINETICS, INC              | 23282W605 | 05/14/2025     | Election of Class III Director to serve for a three-year term and until their successors are duly elected and qualified: John T. Henderson                                                                                                                                                                                                                                                                                                                                  | DIRECTOR ELECTIONS |         980392 |                0 | FOR         |                                   980392 | FOR                         |  |
| CYTOKINETICS, INC              | 23282W605 | 05/14/2025     | Election of Class III Director to serve for a three-year term and until their successors are duly elected and qualified: B. Lynne Parshall                                                                                                                                                                                                                                                                                                                                  | DIRECTOR ELECTIONS |         980392 |                0 | FOR         |                                   980392 | FOR                         |  |
| CYTOKINETICS, INC              | 23282W605 | 05/14/2025     | Election of Class III Director to serve for a three-year term and until their successors are duly elected and qualified: Muna Bhanji                                                                                                                                                                                                                                                                                                                                        | DIRECTOR ELECTIONS |         980392 |                0 | FOR         |                                   980392 | FOR                         |  |
| CYTOKINETICS, INC              | 23282W605 | 05/14/2025     | To approve the amendment and restatement of the Cytokinetics Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under such plan by 5,000,000 shares of common stock and (ii) provide for limitations on the maximum grant value that non-executive directors may receive under such plan of $1,000,000 for annual grants to continuing directors and $1,250,000 for the initial grant to new directors. | COMPENSATION       |         980392 |                0 | FOR         |                                   980392 | FOR                         |  |
| CYTOKINETICS, INC              | 23282W605 | 05/14/2025     | To approve an amendment to Cytokinetics, Incorporated's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common available for issuance by Cytokinetics, Incorporated from 163,000,000 to 326,000,000 shares of common stock.                                                                                                                                                                                                | CAPITAL STRUCTURE  |         980392 |                0 | FOR         |                                   980392 | FOR                         |  |
| CYTOKINETICS, INC              | 23282W605 | 05/14/2025     | To ratify the appointment by the Audit Committee of the Board of Directors of Ernst  Young LLP as Cytokinetics, Incorporated's independent registered publicaccounting firm for the fiscal year ending December 31, 2025.                                                                                                                                                                                                                                                   | AUDIT-RELATED      |         980392 |                0 | FOR         |                                   980392 | FOR                         |  |
| CYTOKINETICS, INC              | 23282W605 | 05/14/2025     | To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.                                                                                                                                                                                                                                                                                                                           | COMPENSATION       |         980392 |                0 | FOR         |                                   980392 | FOR                         |  |
| BioCryst Pharmaceuticals, Inc. | 09058V103 | 06/12/2025     | Vote Board of Director: Steven Galson, MD, MPH                                                                                                                                                                                                                                                                                                                                                                                                                              | DIRECTOR ELECTIONS |        3846154 |                0 | FOR         |                                  3846154 | FOR                         |  |
| BioCryst Pharmaceuticals, Inc. | 09058V103 | 06/12/2025     | Vote Board of Director: Alan Levin                                                                                                                                                                                                                                                                                                                                                                                                                                          | DIRECTOR ELECTIONS |        3846154 |                0 | FOR         |                                  3846154 | FOR                         |  |
| BioCryst Pharmaceuticals, Inc. | 09058V103 | 06/12/2025     | To ratify the selection of Ernst  Young LLP as the Company's independent registered public accountants for 2025.                                                                                                                                                                                                                                                                                                                                                            | AUDIT-RELATED      |        3846154 |                0 | FOR         |                                  3846154 | FOR                         |  |
| BioCryst Pharmaceuticals, Inc. | 09058V103 | 06/12/2025     | To hold a non-binding, advisory vote regarding executive compensation.                                                                                                                                                                                                                                                                                                                                                                                                      | COMPENSATION       |        3846154 |                0 | FOR         |                                  3846154 | FOR                         |  |
| BioCryst Pharmaceuticals, Inc. | 09058V103 | 06/12/2025     | To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan.                                                                                                                                                                                                                                                                                                                             | CAPITAL STRUCTURE  |        3846154 |                0 | FOR         |                                  3846154 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** RP Management, LLC

**By (Signature):** /s/ Jason Mehar

**By (Printed Signature):** /s/ Jason Mehar

**By (Title):** Authorized Signatory

**Date:** 08/29/2025